工程原核生物和酵母菌中生产单克隆抗体和抗体片段研究进展  

Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast

作　　者：赵妍淑 张金华 宋浩 ZHAO Yan-shu;ZHANG Jin-hua;SONG Hao(Key Laboratory of Systems Bioengineering of Ministry of Education,School of Chemical Engineering amd Technology,Tianjin University,Tianjin 300072,China)

机构地区：[1]天津大学化工学院系统生物工程教育部重点实验室,天津300072

出　　处：《中国生物工程杂志》2020年第8期74-83,共10页China Biotechnology

基　　金：国家自然科学基金(21621004)资助项目。

摘　　要：抗体药物和抗体片段药物在药物市场占据了重要的地位,主要通过哺乳动物细胞系统进行生产,操作复杂并且成本高。为了能够克服哺乳动物细胞系统生产抗体药物的弊端,越来越多的抗体及抗体片段在原核细胞及酵母菌中生产,但是产率往往不高并且没有糖基化。从基因转录和翻译的优化、分子伴侣的共表达和抑制蛋白水解降解等方面概述了在原核生物表达系统及酵母菌中提高单克隆抗体和抗体片段产量的研究进展,为未来利用原核生物和酵母菌实现工业化生产单克隆抗体及抗体片段奠定基础。Monoclonal antibodies and antibody fragments play important roles in the pharmaceutical market.They are mainly produced in mammalian cell systems,which have several limitations such as complex manipulation and high costs.For purpose of using cheap drugs,monoclonal antibodies and antibody fragments have been produced in prokaryotes and yeasts.However,the lack of glycosylation and the low yield of antibodies prevent their development.The progress has been made recently in the prokaryotes and yeasts to enhance the antibodies production via optimization of transcription and translation,co-expressing chaperones and inhibiting proteolytic degradation,etc.This will lay the foundation for the industrialization production of antibodies in prokaryotes and yeasts.

关 键 词：单克隆抗体 抗体片段 原核生物 酵母菌 工业化生产 

分 类 号：Q819[生物学—生物工程]